Acute TMA to aHUS: Accelerating Diagnosis and Improving Outcomes-Acute TMA to aHUS: Accelerating Diagnosis and Improving Outcomes

Video Transcription

Video Summary

The webcast reviewed recognition, diagnosis, and management of thrombotic microangiopathies (TMAs), particularly atypical hemolytic uremic syndrome (aHUS), a potentially life-threatening condition involving small-vessel injury.<br /><br />TMA commonly presents with thrombocytopenia, microangiopathic hemolytic anemia (such as schistocytes, elevated LDH, and low haptoglobin), and organ injury. Kidney involvement is common, but neurological, cardiovascular, gastrointestinal, pulmonary, and peripheral vascular complications can occur. Some patients have kidney-limited TMA without the classic blood abnormalities.<br /><br />Clinicians should consider TMA when symptoms and laboratory trends suggest it, promptly test ADAMTS13 to assess for thrombotic thrombocytopenic purpura (TTP), and investigate other possible causes or triggers, including infection, medications, pregnancy, severe hypertension, autoimmune disease, malignancy, and transplantation. A trigger does not exclude complement-mediated disease: it may expose an underlying complement predisposition. Normal complement levels, absent schistocytes, or a platelet count that is not markedly low do not rule out TMA.<br /><br />When a suspected trigger is treated but TMA or kidney injury persists or worsens, clinicians should consider early complement inhibition rather than waiting for genetic results. Genetic testing can inform long-term management but should not delay urgent treatment. Kidney recovery may take months, even after blood counts improve; dialysis alone does not rule out recovery.<br /><br />The speakers emphasized early clinical suspicion, close monitoring, and coordinated care among intensive care, nephrology, hematology, and pharmacy teams. Timely diagnosis and treatment can improve renal outcomes and reduce the risk of lasting organ damage.

Meta Tag

Concept Thrombotic Microangiopathy

Concept Thrombocytopenia

Concept Microangiopathic Hemolytic Anemia

Concept Thrombotic Thrombocytopenic Purpura

Concept Atypical Hemolytic Uremic Syndrome

Concept ADAMTS13

Concept Complement Inhibition

Keywords

thrombotic microangiopathy

atypical hemolytic uremic syndrome

aHUS

ADAMTS13

microangiopathic hemolytic anemia

thrombocytopenia

kidney injury

complement inhibition

TTP

renal outcomes

Thrombotic Microangiopathy

Thrombocytopenia

Microangiopathic Hemolytic Anemia

Thrombotic Thrombocytopenic Purpura

Atypical Hemolytic Uremic Syndrome

ADAMTS13

Complement Inhibition

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.